nodes	percent_of_prediction	percent_of_DWPC	metapath
Atomoxetine—CYP2D6—Hydroxyurea—head and neck cancer	0.168	0.567	CbGbCtD
Atomoxetine—CYP2D6—Vinblastine—head and neck cancer	0.0596	0.201	CbGbCtD
Atomoxetine—Hepatic insufficiency—Hydroxyurea—head and neck cancer	0.048	0.103	CcSEcCtD
Atomoxetine—CYP3A4—Vinblastine—head and neck cancer	0.0379	0.128	CbGbCtD
Atomoxetine—CYP3A4—Docetaxel—head and neck cancer	0.0312	0.105	CbGbCtD
Atomoxetine—HTR1B—trigeminal nerve—head and neck cancer	0.0268	0.158	CbGeAlD
Atomoxetine—HTR1D—trigeminal nerve—head and neck cancer	0.0259	0.153	CbGeAlD
Atomoxetine—HTR1B—cranial nerve—head and neck cancer	0.0191	0.112	CbGeAlD
Atomoxetine—HTR1D—cranial nerve—head and neck cancer	0.0185	0.109	CbGeAlD
Atomoxetine—Epigastric discomfort—Hydroxyurea—head and neck cancer	0.0141	0.0304	CcSEcCtD
Atomoxetine—HTR2A—trigeminal nerve—head and neck cancer	0.0129	0.0758	CbGeAlD
Atomoxetine—Gastrointestinal symptom NOS—Hydroxyurea—head and neck cancer	0.0126	0.0272	CcSEcCtD
Atomoxetine—Pseudoephedrine—IL2—head and neck cancer	0.0109	0.556	CrCbGaD
Atomoxetine—NPY1R—saliva-secreting gland—head and neck cancer	0.0101	0.0594	CbGeAlD
Atomoxetine—Sinus tachycardia—Docetaxel—head and neck cancer	0.00958	0.0206	CcSEcCtD
Atomoxetine—HTR2A—cranial nerve—head and neck cancer	0.00917	0.054	CbGeAlD
Atomoxetine—Gastrointestinal symptom NOS—Fluorouracil—head and neck cancer	0.00909	0.0196	CcSEcCtD
Atomoxetine—Menstruation irregular—Docetaxel—head and neck cancer	0.00697	0.015	CcSEcCtD
Atomoxetine—NPY1R—thyroid gland—head and neck cancer	0.00616	0.0363	CbGeAlD
Atomoxetine—Disorientation—Hydroxyurea—head and neck cancer	0.00603	0.013	CcSEcCtD
Atomoxetine—Hepatic failure—Hydroxyurea—head and neck cancer	0.006	0.0129	CcSEcCtD
Atomoxetine—Pharyngolaryngeal pain—Docetaxel—head and neck cancer	0.00572	0.0123	CcSEcCtD
Atomoxetine—Laryngeal pain—Docetaxel—head and neck cancer	0.00566	0.0122	CcSEcCtD
Atomoxetine—NPY1R—head—head and neck cancer	0.00546	0.0322	CbGeAlD
Atomoxetine—Throat sore—Docetaxel—head and neck cancer	0.00535	0.0115	CcSEcCtD
Atomoxetine—Oropharyngeal discomfort—Docetaxel—head and neck cancer	0.00531	0.0114	CcSEcCtD
Atomoxetine—Coma—Fluorouracil—head and neck cancer	0.00489	0.0105	CcSEcCtD
Atomoxetine—Breast disorder—Hydroxyurea—head and neck cancer	0.00487	0.0105	CcSEcCtD
Atomoxetine—Rhinorrhoea—Docetaxel—head and neck cancer	0.00476	0.0103	CcSEcCtD
Atomoxetine—Rigors—Docetaxel—head and neck cancer	0.00473	0.0102	CcSEcCtD
Atomoxetine—Depression—Vinblastine—head and neck cancer	0.00454	0.00978	CcSEcCtD
Atomoxetine—Dysuria—Hydroxyurea—head and neck cancer	0.00436	0.00938	CcSEcCtD
Atomoxetine—Disorientation—Fluorouracil—head and neck cancer	0.00434	0.00934	CcSEcCtD
Atomoxetine—Bone disorder—Docetaxel—head and neck cancer	0.00427	0.0092	CcSEcCtD
Atomoxetine—Oropharyngeal pain—Docetaxel—head and neck cancer	0.00424	0.00914	CcSEcCtD
Atomoxetine—Drug interaction—Docetaxel—head and neck cancer	0.00416	0.00896	CcSEcCtD
Atomoxetine—Infestation—Hydroxyurea—head and neck cancer	0.00416	0.00895	CcSEcCtD
Atomoxetine—Infestation NOS—Hydroxyurea—head and neck cancer	0.00416	0.00895	CcSEcCtD
Atomoxetine—Hypoaesthesia—Vinblastine—head and neck cancer	0.00407	0.00876	CcSEcCtD
Atomoxetine—Lethargy—Fluorouracil—head and neck cancer	0.00396	0.00853	CcSEcCtD
Atomoxetine—Blood pressure increased—Docetaxel—head and neck cancer	0.00386	0.00831	CcSEcCtD
Atomoxetine—HTR6—head—head and neck cancer	0.00385	0.0226	CbGeAlD
Atomoxetine—NPY1R—lymph node—head and neck cancer	0.00383	0.0225	CbGeAlD
Atomoxetine—HTR1D—connective tissue—head and neck cancer	0.00381	0.0224	CbGeAlD
Atomoxetine—Hallucination—Hydroxyurea—head and neck cancer	0.00371	0.00799	CcSEcCtD
Atomoxetine—Irritability—Fluorouracil—head and neck cancer	0.0037	0.00798	CcSEcCtD
Atomoxetine—Nasopharyngitis—Fluorouracil—head and neck cancer	0.00347	0.00747	CcSEcCtD
Atomoxetine—Angiopathy—Hydroxyurea—head and neck cancer	0.00338	0.00729	CcSEcCtD
Atomoxetine—Chills—Hydroxyurea—head and neck cancer	0.00335	0.00721	CcSEcCtD
Atomoxetine—Vertigo—Vinblastine—head and neck cancer	0.0032	0.00689	CcSEcCtD
Atomoxetine—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.00312	0.00671	CcSEcCtD
Atomoxetine—Hepatic failure—Docetaxel—head and neck cancer	0.00312	0.00671	CcSEcCtD
Atomoxetine—Convulsion—Vinblastine—head and neck cancer	0.00309	0.00664	CcSEcCtD
Atomoxetine—Hot flush—Docetaxel—head and neck cancer	0.00299	0.00645	CcSEcCtD
Atomoxetine—Infestation NOS—Fluorouracil—head and neck cancer	0.00299	0.00644	CcSEcCtD
Atomoxetine—Infestation—Fluorouracil—head and neck cancer	0.00299	0.00644	CcSEcCtD
Atomoxetine—Menopausal symptoms—Docetaxel—head and neck cancer	0.00297	0.00639	CcSEcCtD
Atomoxetine—Warfarin—CYP1A1—head and neck cancer	0.00294	0.15	CrCbGaD
Atomoxetine—Conjunctivitis—Fluorouracil—head and neck cancer	0.00291	0.00626	CcSEcCtD
Atomoxetine—Lethargy—Docetaxel—head and neck cancer	0.00286	0.00615	CcSEcCtD
Atomoxetine—Convulsion—Hydroxyurea—head and neck cancer	0.00281	0.00606	CcSEcCtD
Atomoxetine—Sinusitis—Fluorouracil—head and neck cancer	0.00281	0.00604	CcSEcCtD
Atomoxetine—Anorexia—Vinblastine—head and neck cancer	0.00277	0.00596	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.00275	0.00591	CcSEcCtD
Atomoxetine—Hypoaesthesia—Fluorouracil—head and neck cancer	0.00267	0.00575	CcSEcCtD
Atomoxetine—HTR2A—neck—head and neck cancer	0.00264	0.0155	CbGeAlD
Atomoxetine—Infection—Hydroxyurea—head and neck cancer	0.00263	0.00567	CcSEcCtD
Atomoxetine—Paraesthesia—Vinblastine—head and neck cancer	0.00261	0.00562	CcSEcCtD
Atomoxetine—Nervous system disorder—Hydroxyurea—head and neck cancer	0.0026	0.0056	CcSEcCtD
Atomoxetine—Skin disorder—Hydroxyurea—head and neck cancer	0.00257	0.00554	CcSEcCtD
Atomoxetine—Abdominal pain upper—Docetaxel—head and neck cancer	0.00256	0.00551	CcSEcCtD
Atomoxetine—Breast disorder—Docetaxel—head and neck cancer	0.00253	0.00545	CcSEcCtD
Atomoxetine—Anorexia—Hydroxyurea—head and neck cancer	0.00253	0.00544	CcSEcCtD
Atomoxetine—Decreased appetite—Vinblastine—head and neck cancer	0.00253	0.00544	CcSEcCtD
Atomoxetine—Nasopharyngitis—Docetaxel—head and neck cancer	0.00251	0.00539	CcSEcCtD
Atomoxetine—Constipation—Vinblastine—head and neck cancer	0.00249	0.00535	CcSEcCtD
Atomoxetine—Pain—Vinblastine—head and neck cancer	0.00249	0.00535	CcSEcCtD
Atomoxetine—Fenoprofen—PTGS2—head and neck cancer	0.00241	0.122	CrCbGaD
Atomoxetine—Feeling abnormal—Vinblastine—head and neck cancer	0.00239	0.00516	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Vinblastine—head and neck cancer	0.00238	0.00512	CcSEcCtD
Atomoxetine—Somnolence—Hydroxyurea—head and neck cancer	0.00236	0.00507	CcSEcCtD
Atomoxetine—Dyspepsia—Hydroxyurea—head and neck cancer	0.00233	0.00502	CcSEcCtD
Atomoxetine—HTR1B—head—head and neck cancer	0.00232	0.0136	CbGeAlD
Atomoxetine—Decreased appetite—Hydroxyurea—head and neck cancer	0.0023	0.00496	CcSEcCtD
Atomoxetine—SLC6A3—head—head and neck cancer	0.0023	0.0135	CbGeAlD
Atomoxetine—Abdominal pain—Vinblastine—head and neck cancer	0.0023	0.00495	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.00229	0.00493	CcSEcCtD
Atomoxetine—Fatigue—Hydroxyurea—head and neck cancer	0.00229	0.00492	CcSEcCtD
Atomoxetine—Constipation—Hydroxyurea—head and neck cancer	0.00227	0.00488	CcSEcCtD
Atomoxetine—Pain—Hydroxyurea—head and neck cancer	0.00227	0.00488	CcSEcCtD
Atomoxetine—HTR1D—head—head and neck cancer	0.00224	0.0132	CbGeAlD
Atomoxetine—HTR2C—head—head and neck cancer	0.00222	0.0131	CbGeAlD
Atomoxetine—Vision blurred—Fluorouracil—head and neck cancer	0.0022	0.00474	CcSEcCtD
Atomoxetine—Weight decreased—Docetaxel—head and neck cancer	0.00219	0.00472	CcSEcCtD
Atomoxetine—Feeling abnormal—Hydroxyurea—head and neck cancer	0.00218	0.0047	CcSEcCtD
Atomoxetine—Infestation NOS—Docetaxel—head and neck cancer	0.00216	0.00465	CcSEcCtD
Atomoxetine—Infestation—Docetaxel—head and neck cancer	0.00216	0.00465	CcSEcCtD
Atomoxetine—SLC6A4—head—head and neck cancer	0.00211	0.0124	CbGeAlD
Atomoxetine—Conjunctivitis—Docetaxel—head and neck cancer	0.0021	0.00452	CcSEcCtD
Atomoxetine—Body temperature increased—Hydroxyurea—head and neck cancer	0.0021	0.00451	CcSEcCtD
Atomoxetine—Asthenia—Vinblastine—head and neck cancer	0.00209	0.00449	CcSEcCtD
Atomoxetine—Convulsion—Fluorouracil—head and neck cancer	0.00203	0.00436	CcSEcCtD
Atomoxetine—Myalgia—Fluorouracil—head and neck cancer	0.00199	0.00428	CcSEcCtD
Atomoxetine—Chest pain—Fluorouracil—head and neck cancer	0.00199	0.00428	CcSEcCtD
Atomoxetine—Diarrhoea—Vinblastine—head and neck cancer	0.00199	0.00428	CcSEcCtD
Atomoxetine—Propranolol—CYP1A1—head and neck cancer	0.00197	0.1	CrCbGaD
Atomoxetine—Hypoaesthesia—Docetaxel—head and neck cancer	0.00193	0.00415	CcSEcCtD
Atomoxetine—Dizziness—Vinblastine—head and neck cancer	0.00192	0.00414	CcSEcCtD
Atomoxetine—Urinary tract disorder—Docetaxel—head and neck cancer	0.00191	0.00412	CcSEcCtD
Atomoxetine—Asthenia—Hydroxyurea—head and neck cancer	0.0019	0.00409	CcSEcCtD
Atomoxetine—Urethral disorder—Docetaxel—head and neck cancer	0.0019	0.00409	CcSEcCtD
Atomoxetine—Infection—Fluorouracil—head and neck cancer	0.0019	0.00408	CcSEcCtD
Atomoxetine—HTR2A—connective tissue—head and neck cancer	0.00189	0.0111	CbGeAlD
Atomoxetine—Nervous system disorder—Fluorouracil—head and neck cancer	0.00187	0.00403	CcSEcCtD
Atomoxetine—Tachycardia—Fluorouracil—head and neck cancer	0.00186	0.00401	CcSEcCtD
Atomoxetine—SLC6A2—head—head and neck cancer	0.00186	0.0109	CbGeAlD
Atomoxetine—Vomiting—Vinblastine—head and neck cancer	0.00185	0.00398	CcSEcCtD
Atomoxetine—Headache—Vinblastine—head and neck cancer	0.00182	0.00392	CcSEcCtD
Atomoxetine—Anorexia—Fluorouracil—head and neck cancer	0.00182	0.00391	CcSEcCtD
Atomoxetine—Diarrhoea—Hydroxyurea—head and neck cancer	0.00181	0.0039	CcSEcCtD
Atomoxetine—Cardiac disorder—Docetaxel—head and neck cancer	0.0018	0.00387	CcSEcCtD
Atomoxetine—Flushing—Docetaxel—head and neck cancer	0.0018	0.00387	CcSEcCtD
Atomoxetine—HTR2A—epithelium—head and neck cancer	0.0018	0.0106	CbGeAlD
Atomoxetine—Angiopathy—Docetaxel—head and neck cancer	0.00176	0.00379	CcSEcCtD
Atomoxetine—Dizziness—Hydroxyurea—head and neck cancer	0.00175	0.00377	CcSEcCtD
Atomoxetine—Mediastinal disorder—Docetaxel—head and neck cancer	0.00175	0.00376	CcSEcCtD
Atomoxetine—Chills—Docetaxel—head and neck cancer	0.00174	0.00374	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.00174	0.00374	CcSEcCtD
Atomoxetine—Nausea—Vinblastine—head and neck cancer	0.00173	0.00372	CcSEcCtD
Atomoxetine—Insomnia—Fluorouracil—head and neck cancer	0.00173	0.00371	CcSEcCtD
Atomoxetine—Paraesthesia—Fluorouracil—head and neck cancer	0.00171	0.00369	CcSEcCtD
Atomoxetine—Mental disorder—Docetaxel—head and neck cancer	0.0017	0.00366	CcSEcCtD
Atomoxetine—Somnolence—Fluorouracil—head and neck cancer	0.0017	0.00365	CcSEcCtD
Atomoxetine—Malnutrition—Docetaxel—head and neck cancer	0.00169	0.00363	CcSEcCtD
Atomoxetine—Vomiting—Hydroxyurea—head and neck cancer	0.00169	0.00363	CcSEcCtD
Atomoxetine—Dyspepsia—Fluorouracil—head and neck cancer	0.00168	0.00362	CcSEcCtD
Atomoxetine—Rash—Hydroxyurea—head and neck cancer	0.00167	0.0036	CcSEcCtD
Atomoxetine—Dermatitis—Hydroxyurea—head and neck cancer	0.00167	0.00359	CcSEcCtD
Atomoxetine—Headache—Hydroxyurea—head and neck cancer	0.00166	0.00357	CcSEcCtD
Atomoxetine—Decreased appetite—Fluorouracil—head and neck cancer	0.00166	0.00357	CcSEcCtD
Atomoxetine—Dysgeusia—Docetaxel—head and neck cancer	0.00165	0.00356	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.00165	0.00355	CcSEcCtD
Atomoxetine—Back pain—Docetaxel—head and neck cancer	0.00163	0.00351	CcSEcCtD
Atomoxetine—Pain—Fluorouracil—head and neck cancer	0.00163	0.00351	CcSEcCtD
Atomoxetine—Muscle spasms—Docetaxel—head and neck cancer	0.00162	0.00349	CcSEcCtD
Atomoxetine—HTR2A—trachea—head and neck cancer	0.00159	0.00935	CbGeAlD
Atomoxetine—Nausea—Hydroxyurea—head and neck cancer	0.00157	0.00339	CcSEcCtD
Atomoxetine—Feeling abnormal—Fluorouracil—head and neck cancer	0.00157	0.00338	CcSEcCtD
Atomoxetine—Urticaria—Fluorouracil—head and neck cancer	0.00152	0.00326	CcSEcCtD
Atomoxetine—Syncope—Docetaxel—head and neck cancer	0.00151	0.00326	CcSEcCtD
Atomoxetine—Body temperature increased—Fluorouracil—head and neck cancer	0.00151	0.00325	CcSEcCtD
Atomoxetine—Palpitations—Docetaxel—head and neck cancer	0.00149	0.00321	CcSEcCtD
Atomoxetine—Loss of consciousness—Docetaxel—head and neck cancer	0.00148	0.00319	CcSEcCtD
Atomoxetine—Cough—Docetaxel—head and neck cancer	0.00147	0.00317	CcSEcCtD
Atomoxetine—Convulsion—Docetaxel—head and neck cancer	0.00146	0.00315	CcSEcCtD
Atomoxetine—Chest pain—Docetaxel—head and neck cancer	0.00144	0.00309	CcSEcCtD
Atomoxetine—Myalgia—Docetaxel—head and neck cancer	0.00144	0.00309	CcSEcCtD
Atomoxetine—Arthralgia—Docetaxel—head and neck cancer	0.00144	0.00309	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.00143	0.00307	CcSEcCtD
Atomoxetine—Ketoprofen—PTGS2—head and neck cancer	0.00142	0.0722	CrCbGaD
Atomoxetine—Dry mouth—Docetaxel—head and neck cancer	0.0014	0.00302	CcSEcCtD
Atomoxetine—Infection—Docetaxel—head and neck cancer	0.00137	0.00294	CcSEcCtD
Atomoxetine—Shock—Docetaxel—head and neck cancer	0.00135	0.00292	CcSEcCtD
Atomoxetine—Nervous system disorder—Docetaxel—head and neck cancer	0.00135	0.00291	CcSEcCtD
Atomoxetine—Pruritus—Fluorouracil—head and neck cancer	0.00135	0.00291	CcSEcCtD
Atomoxetine—Tachycardia—Docetaxel—head and neck cancer	0.00134	0.00289	CcSEcCtD
Atomoxetine—Skin disorder—Docetaxel—head and neck cancer	0.00134	0.00288	CcSEcCtD
Atomoxetine—Anorexia—Docetaxel—head and neck cancer	0.00131	0.00283	CcSEcCtD
Atomoxetine—Diarrhoea—Fluorouracil—head and neck cancer	0.00131	0.00281	CcSEcCtD
Atomoxetine—SLC6A2—lymph node—head and neck cancer	0.0013	0.00765	CbGeAlD
Atomoxetine—Dizziness—Fluorouracil—head and neck cancer	0.00126	0.00272	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.00125	0.0027	CcSEcCtD
Atomoxetine—Insomnia—Docetaxel—head and neck cancer	0.00125	0.00268	CcSEcCtD
Atomoxetine—Paraesthesia—Docetaxel—head and neck cancer	0.00124	0.00266	CcSEcCtD
Atomoxetine—Somnolence—Docetaxel—head and neck cancer	0.00122	0.00264	CcSEcCtD
Atomoxetine—Vomiting—Fluorouracil—head and neck cancer	0.00121	0.00261	CcSEcCtD
Atomoxetine—Dyspepsia—Docetaxel—head and neck cancer	0.00121	0.00261	CcSEcCtD
Atomoxetine—Rash—Fluorouracil—head and neck cancer	0.0012	0.00259	CcSEcCtD
Atomoxetine—Dermatitis—Fluorouracil—head and neck cancer	0.0012	0.00259	CcSEcCtD
Atomoxetine—Decreased appetite—Docetaxel—head and neck cancer	0.0012	0.00258	CcSEcCtD
Atomoxetine—Headache—Fluorouracil—head and neck cancer	0.0012	0.00257	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.00119	0.00256	CcSEcCtD
Atomoxetine—Fatigue—Docetaxel—head and neck cancer	0.00119	0.00256	CcSEcCtD
Atomoxetine—Pain—Docetaxel—head and neck cancer	0.00118	0.00253	CcSEcCtD
Atomoxetine—Constipation—Docetaxel—head and neck cancer	0.00118	0.00253	CcSEcCtD
Atomoxetine—Feeling abnormal—Docetaxel—head and neck cancer	0.00113	0.00244	CcSEcCtD
Atomoxetine—Nausea—Fluorouracil—head and neck cancer	0.00113	0.00244	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Docetaxel—head and neck cancer	0.00113	0.00242	CcSEcCtD
Atomoxetine—HTR2A—head—head and neck cancer	0.00111	0.00656	CbGeAlD
Atomoxetine—Body temperature increased—Docetaxel—head and neck cancer	0.00109	0.00234	CcSEcCtD
Atomoxetine—Abdominal pain—Docetaxel—head and neck cancer	0.00109	0.00234	CcSEcCtD
Atomoxetine—CYP2D6—head—head and neck cancer	0.00102	0.00598	CbGeAlD
Atomoxetine—Asthenia—Docetaxel—head and neck cancer	0.000988	0.00213	CcSEcCtD
Atomoxetine—Pruritus—Docetaxel—head and neck cancer	0.000974	0.0021	CcSEcCtD
Atomoxetine—Diarrhoea—Docetaxel—head and neck cancer	0.000942	0.00203	CcSEcCtD
Atomoxetine—Dizziness—Docetaxel—head and neck cancer	0.000911	0.00196	CcSEcCtD
Atomoxetine—Vomiting—Docetaxel—head and neck cancer	0.000876	0.00188	CcSEcCtD
Atomoxetine—Rash—Docetaxel—head and neck cancer	0.000868	0.00187	CcSEcCtD
Atomoxetine—Dermatitis—Docetaxel—head and neck cancer	0.000867	0.00187	CcSEcCtD
Atomoxetine—Headache—Docetaxel—head and neck cancer	0.000863	0.00186	CcSEcCtD
Atomoxetine—Nausea—Docetaxel—head and neck cancer	0.000818	0.00176	CcSEcCtD
Atomoxetine—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.000138	0.00283	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—GRP—head and neck cancer	0.000134	0.00274	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—GRP—head and neck cancer	0.000133	0.00272	CbGpPWpGaD
Atomoxetine—SLC6A4—SIDS Susceptibility Pathways—VEGFA—head and neck cancer	0.000131	0.00268	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—GRP—head and neck cancer	0.000131	0.00267	CbGpPWpGaD
Atomoxetine—CYP3A4—Biological oxidations—NAT2—head and neck cancer	0.000129	0.00263	CbGpPWpGaD
Atomoxetine—CYP3A4—Metapathway biotransformation—NAT2—head and neck cancer	0.000127	0.0026	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—GRP—head and neck cancer	0.000122	0.00249	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—GRP—head and neck cancer	0.000121	0.00247	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—KISS1—head and neck cancer	0.00012	0.00245	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—GRP—head and neck cancer	0.000119	0.00242	CbGpPWpGaD
Atomoxetine—SLC6A4—Circadian rythm related genes—PTEN—head and neck cancer	0.000118	0.00242	CbGpPWpGaD
Atomoxetine—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000114	0.00232	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—KISS1—head and neck cancer	0.000109	0.00223	CbGpPWpGaD
Atomoxetine—CYP2C19—Biological oxidations—GSTM1—head and neck cancer	0.000106	0.00216	CbGpPWpGaD
Atomoxetine—CYP2C19—Metapathway biotransformation—GSTM1—head and neck cancer	0.000104	0.00213	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—KISS1—head and neck cancer	0.000104	0.00213	CbGpPWpGaD
Atomoxetine—CYP2C19—Biological oxidations—CYP1A1—head and neck cancer	0.0001	0.00205	CbGpPWpGaD
Atomoxetine—CYP2C19—Metapathway biotransformation—CYP1A1—head and neck cancer	9.9e-05	0.00202	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—GRP—head and neck cancer	9.89e-05	0.00202	CbGpPWpGaD
Atomoxetine—CYP2D6—Biological oxidations—GSTM1—head and neck cancer	9.74e-05	0.00199	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR downstream signaling—IL2—head and neck cancer	9.7e-05	0.00198	CbGpPWpGaD
Atomoxetine—CYP2D6—Metapathway biotransformation—GSTM1—head and neck cancer	9.61e-05	0.00196	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—KISS1—head and neck cancer	9.47e-05	0.00193	CbGpPWpGaD
Atomoxetine—CYP2D6—Biological oxidations—CYP1A1—head and neck cancer	9.23e-05	0.00189	CbGpPWpGaD
Atomoxetine—CYP2D6—Metapathway biotransformation—CYP1A1—head and neck cancer	9.11e-05	0.00186	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—GRP—head and neck cancer	8.98e-05	0.00183	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—UROD—head and neck cancer	8.83e-05	0.0018	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—IL2—head and neck cancer	8.81e-05	0.0018	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—KISS1—head and neck cancer	8.75e-05	0.00179	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—KISS1—head and neck cancer	8.68e-05	0.00177	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—GRP—head and neck cancer	8.59e-05	0.00175	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—KISS1—head and neck cancer	8.5e-05	0.00174	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—UROD—head and neck cancer	8.12e-05	0.00166	CbGpPWpGaD
Atomoxetine—SLC6A4—Circadian rythm related genes—TP53—head and neck cancer	8.09e-05	0.00165	CbGpPWpGaD
Atomoxetine—HTR2A—SIDS Susceptibility Pathways—VEGFA—head and neck cancer	7.89e-05	0.00161	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—GRP—head and neck cancer	7.8e-05	0.00159	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—NOTCH1—head and neck cancer	7.56e-05	0.00154	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmission across Chemical Synapses—MAPK1—head and neck cancer	7.37e-05	0.0015	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—GRP—head and neck cancer	7.2e-05	0.00147	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—GRP—head and neck cancer	7.15e-05	0.00146	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—MAPK3—head and neck cancer	7.08e-05	0.00145	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—GRP—head and neck cancer	7e-05	0.00143	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—STAT6—head and neck cancer	6.99e-05	0.00143	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—STAT6—head and neck cancer	6.94e-05	0.00142	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	6.85e-05	0.0014	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—STAT6—head and neck cancer	6.8e-05	0.00139	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—MAPK1—head and neck cancer	6.74e-05	0.00138	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—EGFR—head and neck cancer	6.74e-05	0.00138	CbGpPWpGaD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—head and neck cancer	6.65e-05	0.00136	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—KISS1—head and neck cancer	6.44e-05	0.00132	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR downstream signaling—PIK3CA—head and neck cancer	6.44e-05	0.00132	CbGpPWpGaD
Atomoxetine—CYP3A4—Biological oxidations—GSTM1—head and neck cancer	6.37e-05	0.0013	CbGpPWpGaD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—head and neck cancer	6.33e-05	0.00129	CbGpPWpGaD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—head and neck cancer	6.33e-05	0.00129	CbGpPWpGaD
Atomoxetine—CYP3A4—Metapathway biotransformation—GSTM1—head and neck cancer	6.28e-05	0.00128	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—YAP1—head and neck cancer	6.19e-05	0.00126	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—YAP1—head and neck cancer	6.14e-05	0.00125	CbGpPWpGaD
Atomoxetine—HTR2C—G alpha (q) signalling events—PIK3CA—head and neck cancer	6.14e-05	0.00125	CbGpPWpGaD
Atomoxetine—CYP3A4—Biological oxidations—CYP1A1—head and neck cancer	6.04e-05	0.00123	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—YAP1—head and neck cancer	6.01e-05	0.00123	CbGpPWpGaD
Atomoxetine—CYP3A4—Metapathway biotransformation—CYP1A1—head and neck cancer	5.95e-05	0.00122	CbGpPWpGaD
Atomoxetine—SLC6A3—Transmission across Chemical Synapses—HRAS—head and neck cancer	5.91e-05	0.00121	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—PIK3CA—head and neck cancer	5.85e-05	0.00119	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—head and neck cancer	5.77e-05	0.00118	CbGpPWpGaD
Atomoxetine—SLC6A3—Neuronal System—MAPK1—head and neck cancer	5.64e-05	0.00115	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—KISS1—head and neck cancer	5.59e-05	0.00114	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—head and neck cancer	5.49e-05	0.00112	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—head and neck cancer	5.49e-05	0.00112	CbGpPWpGaD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—head and neck cancer	5.49e-05	0.00112	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—HRAS—head and neck cancer	5.41e-05	0.00111	CbGpPWpGaD
Atomoxetine—HTR2A—G alpha (q) signalling events—PIK3CA—head and neck cancer	5.33e-05	0.00109	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—UROD—head and neck cancer	5.31e-05	0.00108	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—GRP—head and neck cancer	5.31e-05	0.00108	CbGpPWpGaD
Atomoxetine—NPY1R—GPCR downstream signaling—AKT1—head and neck cancer	5.26e-05	0.00107	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—IL2—head and neck cancer	5.2e-05	0.00106	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—STAT6—head and neck cancer	5.15e-05	0.00105	CbGpPWpGaD
Atomoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—head and neck cancer	5.08e-05	0.00104	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—CCND1—head and neck cancer	5.07e-05	0.00104	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—PTEN—head and neck cancer	4.9e-05	0.001	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling by GPCR—AKT1—head and neck cancer	4.78e-05	0.000976	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—head and neck cancer	4.77e-05	0.000974	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—GRP—head and neck cancer	4.61e-05	0.000941	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—YAP1—head and neck cancer	4.56e-05	0.000931	CbGpPWpGaD
Atomoxetine—SLC6A3—Neuronal System—HRAS—head and neck cancer	4.53e-05	0.000926	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—STAT6—head and neck cancer	4.47e-05	0.000914	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—VEGFA—head and neck cancer	4.42e-05	0.000903	CbGpPWpGaD
Atomoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—head and neck cancer	4.41e-05	0.000901	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—STAT3—head and neck cancer	4.38e-05	0.000894	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—MAPK3—head and neck cancer	4.18e-05	0.000855	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—MAPK1—head and neck cancer	3.98e-05	0.000813	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—EGFR—head and neck cancer	3.98e-05	0.000813	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—YAP1—head and neck cancer	3.96e-05	0.000808	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	3.89e-05	0.000795	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	3.86e-05	0.000787	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—NAT2—head and neck cancer	3.67e-05	0.000749	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—IL2—head and neck cancer	3.58e-05	0.000731	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—IL2—head and neck cancer	3.55e-05	0.000725	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—IL2—head and neck cancer	3.48e-05	0.00071	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—PIK3CA—head and neck cancer	3.45e-05	0.000706	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—NAT2—head and neck cancer	3.37e-05	0.000689	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—TP53—head and neck cancer	3.34e-05	0.000683	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—IL2—head and neck cancer	3.25e-05	0.000664	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—IL2—head and neck cancer	3.23e-05	0.000659	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—DPYD—head and neck cancer	3.22e-05	0.000657	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—HRAS—head and neck cancer	3.2e-05	0.000653	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—IL2—head and neck cancer	3.16e-05	0.000645	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—YAP1—head and neck cancer	3.05e-05	0.000623	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—DPYD—head and neck cancer	2.96e-05	0.000604	CbGpPWpGaD
Atomoxetine—NPY1R—Signaling Pathways—AKT1—head and neck cancer	2.82e-05	0.000576	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—YAP1—head and neck cancer	2.81e-05	0.000573	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—NOTCH1—head and neck cancer	2.79e-05	0.00057	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—NOTCH1—head and neck cancer	2.77e-05	0.000565	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—NOTCH1—head and neck cancer	2.71e-05	0.000554	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—IL2—head and neck cancer	2.64e-05	0.000538	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—MAPK3—head and neck cancer	2.61e-05	0.000534	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—MAPK3—head and neck cancer	2.59e-05	0.00053	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—MAPK3—head and neck cancer	2.54e-05	0.000519	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—MAPK1—head and neck cancer	2.49e-05	0.000508	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—EGFR—head and neck cancer	2.49e-05	0.000508	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—MAPK1—head and neck cancer	2.47e-05	0.000504	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—EGFR—head and neck cancer	2.47e-05	0.000504	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—MAPK1—head and neck cancer	2.42e-05	0.000493	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—EGFR—head and neck cancer	2.42e-05	0.000493	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—IL2—head and neck cancer	2.39e-05	0.000489	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—PIK3CA—head and neck cancer	2.38e-05	0.000485	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—PIK3CA—head and neck cancer	2.36e-05	0.000481	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—PIK3CA—head and neck cancer	2.31e-05	0.000471	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	2.29e-05	0.000468	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—IL2—head and neck cancer	2.29e-05	0.000467	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—NAT2—head and neck cancer	2.21e-05	0.00045	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—PIK3CA—head and neck cancer	2.16e-05	0.000441	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—PIK3CA—head and neck cancer	2.14e-05	0.000437	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—PIK3CA—head and neck cancer	2.1e-05	0.000428	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—IL2—head and neck cancer	2.08e-05	0.000424	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—NOTCH1—head and neck cancer	2.05e-05	0.00042	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	2e-05	0.000408	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—HRAS—head and neck cancer	2e-05	0.000408	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—HRAS—head and neck cancer	1.98e-05	0.000405	CbGpPWpGaD
Atomoxetine—HTR6—GPCR downstream signaling—AKT1—head and neck cancer	1.94e-05	0.000396	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—HRAS—head and neck cancer	1.94e-05	0.000396	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—DPYD—head and neck cancer	1.93e-05	0.000395	CbGpPWpGaD
Atomoxetine—HTR1D—GPCR downstream signaling—AKT1—head and neck cancer	1.93e-05	0.000393	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—MAPK3—head and neck cancer	1.92e-05	0.000393	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—IL2—head and neck cancer	1.92e-05	0.000392	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—IL2—head and neck cancer	1.91e-05	0.000389	CbGpPWpGaD
Atomoxetine—HTR1B—GPCR downstream signaling—AKT1—head and neck cancer	1.89e-05	0.000385	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—CCND1—head and neck cancer	1.87e-05	0.000382	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—IL2—head and neck cancer	1.87e-05	0.000381	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—CCND1—head and neck cancer	1.86e-05	0.000379	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—YAP1—head and neck cancer	1.83e-05	0.000375	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—TYMS—head and neck cancer	1.83e-05	0.000374	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—MAPK1—head and neck cancer	1.83e-05	0.000374	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—EGFR—head and neck cancer	1.83e-05	0.000374	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—CCND1—head and neck cancer	1.82e-05	0.000371	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GSTM1—head and neck cancer	1.81e-05	0.00037	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PTEN—head and neck cancer	1.81e-05	0.000369	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PTEN—head and neck cancer	1.79e-05	0.000366	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—NOTCH1—head and neck cancer	1.78e-05	0.000364	CbGpPWpGaD
Atomoxetine—HTR6—Signaling by GPCR—AKT1—head and neck cancer	1.76e-05	0.00036	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PTEN—head and neck cancer	1.76e-05	0.000358	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—PIK3CA—head and neck cancer	1.75e-05	0.000357	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling by GPCR—AKT1—head and neck cancer	1.75e-05	0.000357	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—GPX1—head and neck cancer	1.73e-05	0.000354	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—CYP1A1—head and neck cancer	1.72e-05	0.000351	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling by GPCR—AKT1—head and neck cancer	1.71e-05	0.00035	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—TYMS—head and neck cancer	1.69e-05	0.000344	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—MAPK3—head and neck cancer	1.67e-05	0.000341	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GSTM1—head and neck cancer	1.67e-05	0.00034	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—VEGFA—head and neck cancer	1.63e-05	0.000333	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—VEGFA—head and neck cancer	1.62e-05	0.000331	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—STAT3—head and neck cancer	1.62e-05	0.00033	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—STAT3—head and neck cancer	1.6e-05	0.000327	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—GPX1—head and neck cancer	1.6e-05	0.000326	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—MAPK1—head and neck cancer	1.59e-05	0.000325	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—EGFR—head and neck cancer	1.59e-05	0.000325	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—PIK3CA—head and neck cancer	1.59e-05	0.000324	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—VEGFA—head and neck cancer	1.59e-05	0.000324	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—CYP1A1—head and neck cancer	1.58e-05	0.000323	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—STAT3—head and neck cancer	1.57e-05	0.000321	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MAPK3—head and neck cancer	1.54e-05	0.000315	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MAPK3—head and neck cancer	1.53e-05	0.000313	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—PIK3CA—head and neck cancer	1.52e-05	0.00031	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MAPK3—head and neck cancer	1.5e-05	0.000306	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—HRAS—head and neck cancer	1.47e-05	0.0003	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—MAPK1—head and neck cancer	1.47e-05	0.0003	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—EGFR—head and neck cancer	1.47e-05	0.0003	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—MAPK1—head and neck cancer	1.46e-05	0.000298	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—EGFR—head and neck cancer	1.46e-05	0.000298	CbGpPWpGaD
Atomoxetine—HTR2C—GPCR downstream signaling—AKT1—head and neck cancer	1.43e-05	0.000292	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—MAPK1—head and neck cancer	1.43e-05	0.000291	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—EGFR—head and neck cancer	1.43e-05	0.000291	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—IL2—head and neck cancer	1.41e-05	0.000289	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.41e-05	0.000288	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—PIK3CA—head and neck cancer	1.38e-05	0.000282	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—CCND1—head and neck cancer	1.38e-05	0.000281	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PTEN—head and neck cancer	1.33e-05	0.000272	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling by GPCR—AKT1—head and neck cancer	1.3e-05	0.000265	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—HRAS—head and neck cancer	1.28e-05	0.000261	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—PIK3CA—head and neck cancer	1.27e-05	0.00026	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—PIK3CA—head and neck cancer	1.26e-05	0.000258	CbGpPWpGaD
Atomoxetine—HTR2A—GPCR downstream signaling—AKT1—head and neck cancer	1.24e-05	0.000253	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—PIK3CA—head and neck cancer	1.24e-05	0.000253	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—TP53—head and neck cancer	1.23e-05	0.000252	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—IL2—head and neck cancer	1.23e-05	0.000251	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—TP53—head and neck cancer	1.22e-05	0.00025	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—VEGFA—head and neck cancer	1.2e-05	0.000245	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—TP53—head and neck cancer	1.2e-05	0.000245	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—CCND1—head and neck cancer	1.2e-05	0.000244	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—STAT3—head and neck cancer	1.19e-05	0.000243	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—HRAS—head and neck cancer	1.18e-05	0.000241	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—HRAS—head and neck cancer	1.17e-05	0.000239	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PTEN—head and neck cancer	1.16e-05	0.000236	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—HRAS—head and neck cancer	1.15e-05	0.000234	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MAPK3—head and neck cancer	1.14e-05	0.000232	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling by GPCR—AKT1—head and neck cancer	1.13e-05	0.00023	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—TYMS—head and neck cancer	1.1e-05	0.000225	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GSTM1—head and neck cancer	1.09e-05	0.000222	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—MAPK1—head and neck cancer	1.08e-05	0.000221	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—EGFR—head and neck cancer	1.08e-05	0.000221	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—VEGFA—head and neck cancer	1.04e-05	0.000213	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—GPX1—head and neck cancer	1.04e-05	0.000213	CbGpPWpGaD
Atomoxetine—HTR6—Signaling Pathways—AKT1—head and neck cancer	1.04e-05	0.000213	CbGpPWpGaD
Atomoxetine—HTR1D—Signaling Pathways—AKT1—head and neck cancer	1.03e-05	0.000211	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—STAT3—head and neck cancer	1.03e-05	0.000211	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—CYP1A1—head and neck cancer	1.03e-05	0.000211	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PTGS2—head and neck cancer	1.02e-05	0.000209	CbGpPWpGaD
Atomoxetine—HTR1B—Signaling Pathways—AKT1—head and neck cancer	1.01e-05	0.000207	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MAPK3—head and neck cancer	9.87e-06	0.000202	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—MAPK1—head and neck cancer	9.39e-06	0.000192	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PTGS2—head and neck cancer	9.39e-06	0.000192	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—EGFR—head and neck cancer	9.39e-06	0.000192	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—PIK3CA—head and neck cancer	9.38e-06	0.000192	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—TP53—head and neck cancer	9.08e-06	0.000185	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PTEN—head and neck cancer	8.9e-06	0.000182	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—HRAS—head and neck cancer	8.68e-06	0.000177	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PTEN—head and neck cancer	8.19e-06	0.000167	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—PIK3CA—head and neck cancer	8.15e-06	0.000166	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—TP53—head and neck cancer	7.88e-06	0.000161	CbGpPWpGaD
Atomoxetine—HTR2C—Signaling Pathways—AKT1—head and neck cancer	7.67e-06	0.000157	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—HRAS—head and neck cancer	7.54e-06	0.000154	CbGpPWpGaD
Atomoxetine—HTR2A—Signaling Pathways—AKT1—head and neck cancer	6.66e-06	0.000136	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—PIK3CA—head and neck cancer	6.28e-06	0.000128	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PTGS2—head and neck cancer	6.14e-06	0.000125	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—PIK3CA—head and neck cancer	5.78e-06	0.000118	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PTEN—head and neck cancer	5.35e-06	0.000109	CbGpPWpGaD
Atomoxetine—CYP2C19—Metabolism—AKT1—head and neck cancer	5.13e-06	0.000105	CbGpPWpGaD
Atomoxetine—CYP2D6—Metabolism—AKT1—head and neck cancer	4.72e-06	9.64e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—PIK3CA—head and neck cancer	3.78e-06	7.72e-05	CbGpPWpGaD
Atomoxetine—CYP3A4—Metabolism—AKT1—head and neck cancer	3.09e-06	6.3e-05	CbGpPWpGaD
